Extensive lymph node surgery may not be necessary for some patients with melanoma

Share :
Published: 30 May 2015
Views: 2552
Rating:
Save
Prof Claus Garbe - University of Tübingen, Tübingen, Germany

Prof Garbe talks to ecancertv at ASCO 2015 about a randomised study which found that surgical removal of the lymph nodes surrounding a melanoma tumour after a positive lymph node biopsy (melanoma found in node) does not improve survival.

Read the news article and watch the press conference for more.

ASCO 2015

Extensive lymph node surgery may not be necessary for some patients with melanoma

Prof Claus Garbe - University of Tübingen, Tübingen, Germany


You’ve been looking at sentinel lymph node biopsy positive patients with melanoma. Why were you looking at them, what did you want to find out?

The recommendation today is that sentinel lymph node positive patients should receive a complete lymphadenectomy which is major surgery and also has adverse events like a rather high rate of permanent lymphedema. So our question was do these patients benefit in respect to survival from the complete lymphadenectomy? And in order to answer that we conducted a randomised trial within the German Dermatological Co-operative Oncology Group, forty centres.

You had the revolutionary idea that maybe not doing anything might be a good idea.

Yes, and so indeed we needed nine years in order to enrol 483 patients. Two-thirds of the patients refused to participate in this trial because they wanted not to be randomised either to surgery or to observation but they wanted to decide on their own.

They wanted action which people often do want action. But what happened?

So the outcome is that we do not find a survival benefit. So in terms of distant metastasis free survival we have only a difference of 0.3% after three years. Similarly, for the melanoma specific overall survival the curves overlap completely and this is also true for the recurrence free survival. The only difference is we have a higher local control in the lymph node basin after performing a complete lymphadenectomy. But the difference is not large, 14% recurrences in the lymph node basin in the observation group and 8% recurrences in the lymphadenectomy group, so it’s a question whether this is clinically meaningful.

What are the clear clinical implications coming from this then?

I think we have to really think whether we can recommend our patients the complete lymphadenectomy when they have a positive sentinel node. I guess the answer in Europe will be no and in the US probably they want to wait until their study shows the same results.

Now, this is a phase III study so what do you think, then, is the bottom line coming out of this?

Probably we will decide in Germany not to recommend the complete lymphadenectomy in positive sentinel lymph node patients. And I expect that we will have this in our guidelines soon.

Related Videos

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
2 Jun 2024

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel -  MD Anderson Cancer Center, Houston, USA )
2 Nov 2023

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC

Dr Neil Gross - MD Anderson Cancer Center, Houston, USA
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )
27 Oct 2023

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence

Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA
Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence ( Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA )
3 May 2023

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

The role of multidisciplinary tumour board in managing stage 3 lung cancer

Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland
The role of multidisciplinary tumour board in managing stage 3 lung cancer ( Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland )
1 Feb 2023

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )
26 Jan 2023